Cargando…
The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody
We have previously demonstrated that KS-133 is a specific and potent antagonist of vasoactive intestinal peptide receptor 2 (VIPR2). We have also shown that vasoactive intestinal peptide–VIPR2 signaling affects the polarity and activation of tumor-associated macrophages, which is another strategy fo...
Autores principales: | Sakamoto, Kotaro, Kittikulsuth, Wararat, Miyako, Eijiro, Steeve, Akumwami, Ishimura, Rika, Nakagawa, Shinsaku, Ago, Yukio, Nishiyama, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321640/ https://www.ncbi.nlm.nih.gov/pubmed/37405999 http://dx.doi.org/10.1371/journal.pone.0286651 |
Ejemplares similares
-
Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders
por: Sakamoto, Kotaro, et al.
Publicado: (2021) -
Probing the VIPR2 Microduplication Linkage to Schizophrenia in Animal and Cellular Models
por: Ago, Yukio, et al.
Publicado: (2021) -
Vasoactive intestinal peptide–VIPR2 signaling regulates tumor cell migration
por: Asano, Satoshi, et al.
Publicado: (2022) -
Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors
por: Sakamoto, Kotaro, et al.
Publicado: (2023) -
Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice
por: Zhang, Anqi, et al.
Publicado: (2021)